Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 56 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
31 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
ConvEyXo from Charleroi, company number BE0725874259, closed financial year 2025 with a result of € -1.6 million after tax. For that financial year ConvEyXo recorded a gross margin of € -45,230 and equity of € 1.4 million. Compared with financial year 2024, the result moved from € -946,720 to € -1.6 million. The company made a loss. The buffer shrank hard: equity is 53 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 29, 2026.
€ 1.4 million
▼ 53% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -1.6 million
▼ 70 % more loss than in 2024
Profit after tax over the fiscal year.
€ 1.6 million
▲ 5% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -3.6 million.
People and assets in 2025
3.1
▲ 0.3 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 326,835
▲ 55% vs 2024
€ 105,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 74,532
▲ € 65,085 vs 2024
Of which on lease € 49,341.
Debts at end 2025
€ 7.1 million
▲ 137% vs 2024
€ 3.9 million is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.
€ 362,738
▲ 28% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 26,098
▼ 43% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -439,175 | € -440,265 | € -76,396 | € -45,230 | ▲ € 31,165 |
| Profit after taxes | € -1,412,096 | € -1,088,660 | € -946,720 | € -1,605,634 | ▼ € 658,914 |
| Equity | € 1,811,744 | € 2,989,604 | € 2,961,626 | € 1,388,840 | ▼ 53% |
| Total debts | € 1,493,134 | € 2,257,588 | € 4,974,279 | € 8,884,997 | ▲ 79% |
| Cash | € 2,102,344 | € 84,758 | € 1,535,662 | € 1,608,265 | ▲ 5% |
| Retained profit | € -3,440,161 | € -1,088,660 | € -2,035,380 | € -3,641,014 | ▼ € 1.6 million |
| Bank debt | € 57,861 | € 1,824,956 | € 3,011,773 | € 7,142,078 | ▲ 137% |
| Balance sheet total | € 3,304,878 | € 5,247,192 | € 7,935,905 | € 10,273,837 | ▲ 29% |
| Employees (FTE) | 1 | 1.4 | 2.8 | 3.1 | ▲ 0.3 |
Key figures of ConvEyXo, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to ConvEyXo?
What happened at ConvEyXo in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Michael Scholl stepped down as director. NBB
- TONGLET CONSULT SRL stepped down as director. NBB
- JPP CONSULTING SRL stepped down as director. NBB
- FONDS DE CAPITAL A RISQUE 2020 SA stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 1.6 million. Source: NBB ↗
- Michael Scholl became a director. NBB
- TONGLET CONSULT SRL became a director. NBB
- JPP CONSULTING SRL became a director. NBB
In short
From € 1.4 million loss in 2022 to € 1.6 million loss in 2025.
Paid € 2,169 in corporate taxes since 2022.
Management
The stake of JSMAL BioTech Consulting, FONDS DE CAPITAL A RISQUE 2020 comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
ConvEyXoThe shares are held by JSMAL BioTech Consulting (100%) and FONDS DE CAPITAL A RISQUE 2020 (27.3%).
Directors
According to the 2025 annual accounts
Director · represented by Jean-Paul PRIEELS
Also active at: CURAVAC EUROPE, PDC line Pharma, XomeXBio, Exo-Harvest
since 2022 · until 2028
Michael Scholl
Director
since 2023 · until 2029
Director · represented by Frédéric Tonglet
Also active at: XomeXBio, Exo-Harvest
since 2023 · until 2029
FONDS DE CAPITAL A RISQUE 2020 SA
Director · represented by Helena Posioz
Also active at: MintT, LYS MEDICAL, APAXEN, STEEL ESTATE, Magic Loom, DIGIT 89, KOKUMA, Stellaris
since 2022 · until 2028
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue Clément Ader 10
6041 Charleroi
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 31 companies are registered at this address.
All companies at this address →Brussels South Charleroi BioPark Dev
€ 80,186 gross margin · 2025
ImmunXperts
€ 393,338 gross margin · 2024
LYS MEDICAL same network
€ -309,203 gross margin · 2025
SPECTRALYS BIOTECH
€ 143,689 gross margin · 2025
ProtonW.be
€ -7,643 gross margin · 2025
+26 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0725.874.259
- VAT number
- BE 0725.874.259
- Registered office
- Rue Clément Ader 10, 6041 Charleroi
- Names & denominations
- ConvEyXo
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 30 April 2019
- Peppol
- Active · Active since 20 Nov 2020
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Speur- en ontwikkelingswerk op het gebied van de maatschappij- en geesteswetenschappen
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied